Promazine

Not to be confused with Bromazine.
Promazine
Clinical data
AHFS/Drugs.comMicromedex Detailed Consumer Information
MedlinePlusa600010
Drug classTypical antipsychotic
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding94%
Elimination half-life20-40 hr
Identifiers
  • N,N-dimethyl-3-(10H-phenothiazin-10-yl)-propan-1-amine
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.000.347 Edit this at Wikidata
Chemical and physical data
FormulaC17H20N2S
Molar mass284.42 g·mol−1
3D model (JSmol)
  • CN(C)CCCN1c2ccccc2Sc3c1cccc3
  • InChI=1S/C17H20N2S/c1-18(2)12-7-13-19-14-8-3-5-10-16(14)20-17-11-6-4-9-15(17)19/h3-6,8-11H,7,12-13H2,1-2H3 checkY
  • Key:ZGUGWUXLJSTTMA-UHFFFAOYSA-N checkY
  (verify)

Promazine (brand name Sparine among others),[2] is used as a short-term add-on treatment for psychomotor agitation.[3][4] Its approved uses in people is limited, but is used as a tranquilizer in veterinary medicine.[3] It has weak antipsychotic effects but is generally not used to treat psychoses.[3]

It acts similar to chlorpromazine and causes sedation.[3] It has predominantly anticholinergic side effects, though extrapyramidal side effects are not uncommon. It belongs to the typical antipsychotic and phenothiazine class of drugs.[5]

Promazine was approved for medical use in the United States in the 1950s, although it is no longer commercially available there.[2][6]

  1. ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  2. ^ a b "Promazine (Primazine, Prozine)". Davis's Drug Guide. Retrieved 6 August 2021.
  3. ^ a b c d Davis C (2007). "Promazine". In Enna SJ, Bylund DB (eds.). X Pharm: The Comprehensive Pharmacology Reference. Elsevier. pp. 1–6. doi:10.1016/B978-008055232-3.62472-9. ISBN 978-0-08-055232-3.
  4. ^ Cite error: The named reference BNF was invoked but never defined (see the help page).
  5. ^ Pagliaro LA, Pagliaro AM (1999). "PPDR: Promazine". Psychologist's Neuropsychotropic Desk Reference. Philadelphia: Brunner/Mazel. p. 535. ISBN 978-1-138-00968-4.
  6. ^ "Drugs@FDA: FDA-Approved Drugs". New Drug Application (NDA): 010942 Sparine. U.S. Food and Drug Administration.